Azienda Ospedaliero-Universitaria Maggiore Della Carita
- Address
- lock Available on a paid plan
Neurology and Neurodegenerative Disease Research
At Azienda Ospedaliero-Universitaria Maggiore Della Carita, the Department of Neurology and ALS Center support studies focused on nervous system diseases and related quality-of-life outcomes. Research includes major conditions such as Amyotrophic Lateral Sclerosis, Alzheimer’s disease, and Parkinson’s disease, with trials aimed at testing new symptom-relief approaches and improving daily functioning.
- Neurodegenerative disease management, including ALS, Alzheimer’s disease, and Parkinson’s disease
- Evaluation of treatments designed to improve quality of life and patient comfort
- Supportive care research in a specialist neurology setting
The site’s neurology expertise also connects with broader work on neurological complications and brain-related outcomes, reflecting a strong focus on practical, patient-centered care.
Hematology and Lymphoma Studies
This research program includes several trials in hemic and lymphatic diseases, especially follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, chronic lymphocytic leukemia, and multiple myeloma. The studies are designed to compare new immunotherapies and targeted treatments with current standards of care, with the goal of improving disease control and response rates.
- Relapsed or refractory follicular lymphoma and marginal zone lymphoma
- Newly diagnosed and previously treated aggressive B-cell lymphoma
- Multiple myeloma and chronic lymphocytic leukemia treatment strategies
These trials show a strong interest in advancing blood cancer care through more effective and better-tolerated therapies.
Breast Cancer and Other Solid Tumor Research
The site is active in neoplasms, with studies in early breast cancer, advanced breast cancer, non-small cell lung cancer, head and neck squamous cell carcinoma, and prostate cancer. Research here often aims to determine whether newer hormone-based, immune-based, or targeted approaches can improve progression-free survival and reduce recurrence.
- ER-positive, HER2-negative breast cancer in early and advanced settings
- Non-small cell lung cancer with specific molecular features
- Prostate cancer and head and neck cancer treatment optimization
These oncology studies reflect a broad effort to refine treatment effectiveness across both common and more specialized cancer types.
Metabolic, Liver, and Cardiovascular Research
Clinical trials at this center also cover nutritional and metabolic diseases, digestive system diseases, and cardiovascular diseases. Key conditions include obesity, type 2 diabetes, MASH, NASH, heart failure, and atrial fibrillation, with studies focused on improving long-term risk reduction, liver health, and cardiometabolic outcomes.
- Obesity, overweight, and type 2 diabetes management
- Liver disease research in NASH and MASH with fibrosis
- Heart failure and stroke prevention in cardiovascular disease
These trials combine prevention and treatment goals, aiming to better control chronic disease progression and associated complications.
Inflammatory, Autoimmune, and Kidney Disease Research
The site also conducts studies in immune system diseases and related inflammatory conditions, including lupus nephritis, autoimmune disease, fibrosis, and chronic kidney disease. The main purpose of this research is to evaluate whether targeted therapies can reduce inflammation, protect organ function, and improve clinical outcomes.
- Lupus nephritis and other immune-mediated kidney conditions
- Autoimmune and inflammatory disease treatment evaluation
- Fibrosis-related disease progression and organ protection
These investigations add an important translational dimension to the Novara research portfolio, linking immune control with better long-term health outcomes.
Ophthalmology and Public Health-Oriented Studies
In addition to specialty disease areas, the research portfolio includes eye diseases such as glaucoma, as well as studies with environment and public health relevance. These trials aim to improve visual preservation, support safer care strategies, and evaluate therapies that may have broader quality-of-life benefits.
- Glaucoma research focused on preserving vision
- Public health-oriented clinical studies with patient-centered outcomes
- Supportive care approaches that may improve everyday functioning
Across these areas, the site combines focused specialty care with broader efforts to improve outcomes that matter to patients in daily life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 23 therapeutic areas and 15 of 351 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 336 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 73 by active trials.
- 1Merck Sharp & Dohme LLC6active
lock +72 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +48 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Azienda Ospedaliero-Universitaria Maggiore Della Carita
lock Showing 1 of 244 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy | Chiesi Farmaceutici S.p.A. | Phase III | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 351 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 30 | Unknown | 2014-05-15 | 2025-07-29 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.